The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2016
Filed:
Sep. 06, 2012
Kenji Izuhara, Saga, JP;
Shoichiro Ohta, Saga, JP;
Kazuhiko Arima, Saga, JP;
Hiroshi Shiraishi, Saga, JP;
Shoichi Suzuki, Saga, JP;
Tomoaki Hoshino, Kurume, JP;
Yoshinori Azuma, Sagamihara, JP;
Junya Ono, Sagamihara, JP;
Kenji Izuhara, Saga, JP;
Shoichiro Ohta, Saga, JP;
Kazuhiko Arima, Saga, JP;
Hiroshi Shiraishi, Saga, JP;
Shoichi Suzuki, Saga, JP;
Tomoaki Hoshino, Kurume, JP;
Yoshinori Azuma, Sagamihara, JP;
Junya Ono, Sagamihara, JP;
SHINO-TEST CORPORATION, Tokyo, JP;
SAGA UNIVERSITY, Saga-Shi, JP;
KURUME UNIVERSITY, Kurume-Shi, JP;
Abstract
The present invention provides a method and a reagent for measuring periostin contained in a sample with improved accuracy, a method for improving accuracy in measurement of periostin, and a method of testing for pulmonary fibrosis or interstitial pneumonia with improved accuracy. The antibody of the present invention binds to at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin or a cleavage product thereof. The method and the reagent for measuring periostin and the method for improving accuracy in periostin measurement of the present invention is characterized by detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin. The method of testing for pulmonary fibrosis or interstitial pneumonia of the present invention includes the steps of a) measuring the amount or concentration of periostin in a sample derived from a subject, which measuring includes detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin and b) comparing the amount or concentration of the periostin in the sample derived from the subject with an amount or concentration of periostin in a sample derived from a living body not suffering from pulmonary fibrosis and interstitial pneumonia.